This content is machine translated Dupilumab for COPD and asthma Exacerbations reduced and lung function improved The monoclonal antibody dupilumab blocks the common receptor component for interleukin (IL)-4 and IL-13, the central drivers of type 2 inflammation. It has been approved in Switzerland since 2019, and…
View Post 16 min This content is machine translated Moderate to severe atopic dermatitis Changing therapeutic landscape – broad arsenal of treatment options New therapies in the form of specific antibodies and “small molecules” have ushered in a new era. Biologics intervene in the inflammatory process of atopic dermatitis by targeting individual cytokines.… CME-Test
